DK3999180T3 - Polymorfer af (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1 -methyl-1H-pyrazol-4-carboxamid - Google Patents
Polymorfer af (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1 -methyl-1H-pyrazol-4-carboxamid Download PDFInfo
- Publication number
- DK3999180T3 DK3999180T3 DK20753562.6T DK20753562T DK3999180T3 DK 3999180 T3 DK3999180 T3 DK 3999180T3 DK 20753562 T DK20753562 T DK 20753562T DK 3999180 T3 DK3999180 T3 DK 3999180T3
- Authority
- DK
- Denmark
- Prior art keywords
- inden
- oxadiazol
- polymorphs
- carboxamide
- pyrazole
- Prior art date
Links
- IOVAZWDIRCRMTM-OAHLLOKOSA-N N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methylpyrazole-4-carboxamide Chemical compound C(C)C1=NC(=NO1)C=1C=C2CC[C@H](C2=CC=1)NC(=O)C=1C=NN(C=1)C IOVAZWDIRCRMTM-OAHLLOKOSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962875350P | 2019-07-17 | 2019-07-17 | |
PCT/US2020/042387 WO2021011807A1 (en) | 2019-07-17 | 2020-07-16 | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3999180T3 true DK3999180T3 (da) | 2024-05-21 |
Family
ID=71995103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK20753562.6T DK3999180T3 (da) | 2019-07-17 | 2020-07-16 | Polymorfer af (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1 -methyl-1H-pyrazol-4-carboxamid |
Country Status (23)
Country | Link |
---|---|
US (1) | US20220315571A1 (da) |
EP (1) | EP3999180B1 (da) |
JP (1) | JP2022540668A (da) |
KR (1) | KR20220084008A (da) |
CN (1) | CN114555590B (da) |
AU (1) | AU2020313965A1 (da) |
BR (1) | BR112022000494A2 (da) |
CA (1) | CA3144975A1 (da) |
CL (1) | CL2022000054A1 (da) |
DK (1) | DK3999180T3 (da) |
ES (1) | ES2980885T3 (da) |
FI (1) | FI3999180T3 (da) |
HR (1) | HRP20240713T1 (da) |
HU (1) | HUE066891T2 (da) |
IL (1) | IL289875A (da) |
LT (1) | LT3999180T (da) |
MX (1) | MX2022000504A (da) |
PL (1) | PL3999180T3 (da) |
PT (1) | PT3999180T (da) |
RS (1) | RS65611B1 (da) |
SI (1) | SI3999180T1 (da) |
TW (1) | TW202116763A (da) |
WO (1) | WO2021011807A1 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA51620A (fr) | 2018-01-19 | 2020-11-25 | Cytokinetics Inc | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques |
US11964967B2 (en) | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
JP7447089B2 (ja) | 2018-08-31 | 2024-03-11 | サイトキネティックス, インコーポレイテッド | 心筋サルコメア阻害剤 |
KR20240015622A (ko) | 2021-03-04 | 2024-02-05 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
IL310140A (en) | 2021-07-16 | 2024-03-01 | Cytokinetics Inc | Methods for treating hypertrophic cardiomyopathy |
WO2023015184A1 (en) | 2021-08-03 | 2023-02-09 | Cytokinetics, Inc. | Process for preparing aficamten |
TW202423423A (zh) | 2022-07-20 | 2024-06-16 | 美商胞質動力學公司 | 治療非阻塞性肥厚性心肌病之方法 |
US20240115554A1 (en) | 2022-08-04 | 2024-04-11 | Cytokinetics, Incorporated | Methods for treating obstructive hypertrophic cardiomyopathy |
WO2024134498A1 (en) | 2022-12-22 | 2024-06-27 | Assia Chemical Industries Ltd. | Solid state forms of aficamten and process for preparation thereof |
WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA51620A (fr) * | 2018-01-19 | 2020-11-25 | Cytokinetics Inc | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques |
-
2020
- 2020-07-16 PT PT207535626T patent/PT3999180T/pt unknown
- 2020-07-16 BR BR112022000494A patent/BR112022000494A2/pt unknown
- 2020-07-16 SI SI202030443T patent/SI3999180T1/sl unknown
- 2020-07-16 DK DK20753562.6T patent/DK3999180T3/da active
- 2020-07-16 FI FIEP20753562.6T patent/FI3999180T3/fi active
- 2020-07-16 HR HRP20240713TT patent/HRP20240713T1/hr unknown
- 2020-07-16 HU HUE20753562A patent/HUE066891T2/hu unknown
- 2020-07-16 CN CN202080059660.0A patent/CN114555590B/zh active Active
- 2020-07-16 WO PCT/US2020/042387 patent/WO2021011807A1/en active Application Filing
- 2020-07-16 ES ES20753562T patent/ES2980885T3/es active Active
- 2020-07-16 MX MX2022000504A patent/MX2022000504A/es unknown
- 2020-07-16 LT LTEPPCT/US2020/042387T patent/LT3999180T/lt unknown
- 2020-07-16 JP JP2022502215A patent/JP2022540668A/ja active Pending
- 2020-07-16 EP EP20753562.6A patent/EP3999180B1/en active Active
- 2020-07-16 TW TW109124093A patent/TW202116763A/zh unknown
- 2020-07-16 AU AU2020313965A patent/AU2020313965A1/en active Pending
- 2020-07-16 KR KR1020227004639A patent/KR20220084008A/ko unknown
- 2020-07-16 RS RS20240598A patent/RS65611B1/sr unknown
- 2020-07-16 CA CA3144975A patent/CA3144975A1/en active Pending
- 2020-07-16 PL PL20753562.6T patent/PL3999180T3/pl unknown
- 2020-07-16 US US17/627,599 patent/US20220315571A1/en active Pending
-
2022
- 2022-01-10 CL CL2022000054A patent/CL2022000054A1/es unknown
- 2022-01-16 IL IL289875A patent/IL289875A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3144975A1 (en) | 2021-01-21 |
US20220315571A1 (en) | 2022-10-06 |
AU2020313965A1 (en) | 2022-03-03 |
IL289875A (en) | 2022-03-01 |
JP2022540668A (ja) | 2022-09-16 |
SI3999180T1 (sl) | 2024-07-31 |
KR20220084008A (ko) | 2022-06-21 |
HRP20240713T1 (hr) | 2024-09-13 |
EP3999180A1 (en) | 2022-05-25 |
PT3999180T (pt) | 2024-06-25 |
MX2022000504A (es) | 2022-02-10 |
CN114555590A (zh) | 2022-05-27 |
LT3999180T (lt) | 2024-08-26 |
BR112022000494A2 (pt) | 2022-03-03 |
TW202116763A (zh) | 2021-05-01 |
HUE066891T2 (hu) | 2024-09-28 |
CN114555590B (zh) | 2024-09-10 |
FI3999180T3 (fi) | 2024-06-18 |
PL3999180T3 (pl) | 2024-09-23 |
WO2021011807A1 (en) | 2021-01-21 |
ES2980885T3 (es) | 2024-10-03 |
RS65611B1 (sr) | 2024-07-31 |
EP3999180B1 (en) | 2024-05-08 |
CL2022000054A1 (es) | 2022-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3999180T3 (da) | Polymorfer af (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1 -methyl-1H-pyrazol-4-carboxamid | |
DK3713919T3 (da) | Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid | |
SI3464265T1 (sl) | Polimorfi N-((3-fluoro-4-metoksipiridin-2-IL)metil)-3-(metoksimetil)- 1-((4-(2-oksopiridin-1-IL)metil)fenil)pirazol-4-karboksamida kot zaviralci kalikreina | |
CL2020002056A1 (es) | Formas cristalinas novedosas. | |
MA55131A (fr) | Nouveaux composés hétérocycliques | |
IL289881A (en) | Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide | |
AR100251A1 (es) | Inhibidores de la dematilasa-1 especifica de lisina | |
IL287030A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy | |
UY37517A (es) | Métodos de síntesis de compuestos tiazoles sustituidos | |
MA55019A (fr) | Forme cristalline du monohydrate de 1-(1-oxo-1,2-dihydroisoquinoléin-5-yl)-5-(trifluorométhyl)-(2-(trifluorométhyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide | |
ES2721280T3 (es) | Nuevos inhibidores de la FYN quinasa | |
DK3666768T3 (da) | F r e m g a n g s m å d e t i l f r e m s t i l l i n g a f e n k r y s t a l l i n s k f o r m a f 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat; krystallinsk form af 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-YL)-1-methylpiperidin-4-YL)-3-(4-cyanophenyl)ure | |
DK3298008T3 (da) | Krystallinsk form af forbindelsen (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propan-1,2-diol | |
IL272992A (en) | Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide | |
DK3908584T3 (da) | Krystalformer af 1-(1,2-dimethylpropyl)-n-ethyl-5-methyl-n-pyridazin-4-ylpyrazol-4-carboxamid | |
RU2017125134A (ru) | Применение лигандов сигма-рецепторов при остеоартрите | |
DK3298006T3 (da) | Antifungal 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorphenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-n-(2-hydroxycyclohexyl)benzamid eller et farmaceutisk acceptabelt salt deraf | |
DK3633331T3 (da) | Overvågning af maskinvibration | |
DK3585785T3 (da) | Fremgangsmåde til fremstilling af methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h | |
MA50805A (fr) | Formes cristallines de n-(4-(4-(cyclopropylméthyl) pipérazine-1-carbonyl)phényl)quinoléine-8-sulfonamide | |
RU2024122437A (ru) | Замещенное производное тетрагидроизохинолина, как позитивный аллостерический модулятор d1 | |
UA97632U (xx) | Ферум(іі) 2-(5-(3-нітрофеніл)-4-аміно-1,2,4-триазол-3-ілтіо)ацетат, що виявляє гіпоглікемічну активність | |
UA97633U (xx) | 3-((2-хлоретил)тіо)-5-(4-метоксифеніл)-1н-1,2,4-триазол, що проявляє гіпоглікемічну активність | |
EA201891102A1 (ru) | Термодинамически стабильная кристаллическая модификация 2-метил-n-(5-метил-1,3,4-оксадиазол-2-ил)-3-(метилсульфонил)-4-(трифторметил)бензамида | |
RU2015153084A (ru) | Замещенные 3-(3-пиридил)изоксазолидины, обладающие фунгицидной активностью |